Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators
Nucleotide-based drug candidates such as antisense oligonucleotides, aptamers, immunoreceptor-activating nucleotides, or (anti)microRNAs hold great therapeutic promise for many human diseases. Phosphorothioate (PS) backbone modification of nucleotide-based drugs is common practice to protect these promising drug candidates from rapid degradation by plasma and intracellular nucleases. Effects of the changes in physicochemical properties associated with PS modification on platelets have not been...[Show more]
|Collections||ANU Research Publications|
|Source:||Journal of Experimental Medicine|
|Access Rights:||Open Access|
|01_Flierl_Phosphorothioate_backbone_2015.pdf||2.13 MB||Adobe PDF|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.